BusinessUpdated 17 min ago
Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway

The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.
Continue reading on BusinessLine
Read full story Hello Headlines links you to the original publisher for the full story.




